CERN Asks For Advance

GENEVA—A cash crisis has forced CERN (the European Center for Nuclear Research) to ask member countries for an advance on this year's subscription. Although this year's operating budget has not been set (the latest estimate is ($1.2 billion), CERN has suffered from the escalating costs of building a new electron/positron collider (LEP). The facility, scheduled to open in 1989, will study the recently discovered W and Z particles. Germany and France, which together contribute nearly one-hal

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
GENEVA—A cash crisis has forced CERN (the European Center for Nuclear Research) to ask member countries for an advance on this year's subscription. Although this year's operating budget has not been set (the latest estimate is ($1.2 billion), CERN has suffered from the escalating costs of building a new electron/positron collider (LEP). The facility, scheduled to open in 1989, will study the recently discovered W and Z particles. Germany and France, which together contribute nearly one-half of its budget, have agreed to pay their share several months early.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Genome Modeling and Design: From the Molecular to Genome Scale

Genome Modeling and Design: From the Molecular to Genome Scale

Twist Bio 
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

DNA and pills, conceptual illustration of the relationship between genetics and therapeutic development

Multiplexing PCR Technologies for Biopharmaceutical Research

Thermo Fisher Logo
Discover how to streamline tumor-infiltrating lymphocyte production.

Producing Tumor-infiltrating Lymphocyte Therapeutics

cytiva logo

Products

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery